Comparative efficacy of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer in 64 cases

Abstract

Objective To analyze the efficacy and safety of liposomal paclitaxel in comparison with paclitaxel for patients with non-small-cell lung cancer. Methods Sixty-four patients with non-small-cell lung cancer were randomized to be treated with liposomal paclitaxel or paclitaxel 150 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on days 1 to 3 of a 3-week cycle, all patients received six cycles of this regimen. Results Among 64 patients evaluable for response, the response in the primary tumor and the toxicity were observed, response rates of patients with non-small-cell lung cancer was 28.13% for liposomal paclitaxel plus cisplatin group and 21.88% for paclitaxel plus cisplatin group. There was no statistical significant difference in efficacy between the two groups( P ＞0.05 ). The major hematologic toxicity was neutropenia but no statistical significant difference( P ＞0.05 ). The major nonhematologic toxicity were nausea, vomiting, losing hair, muscle pain, joint pain, dyspnea and skin rash. The nausea, vomiting, muscle pain, joint pain, dyspnea and skin rash were statistical significant difference between the two groups in safety ( P ＜ 0.05 ). Conclusions Liposomal paclitaxel is effective and safe for the treatment of non-small-cell lung cancer. The chemotherapy regimen of liposomal paclitaxel and cisplatin is effective for the treatment of non-small-cell lung cancer, with considerable effect of traditional paclitaxel, but the incidence of allergic and non-hematologic toxic reaction are lower than conventional paclitaxel. Key words: Liposomal paclitaxel; Paclitaxel injection; Non-small-cell lung cancer; Randomized controlled trials; Multicenter studies